Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow traded up 0.95% to 37,824.10 while the NASDAQ rose 1.39% to 15,264.30. The S&P 500 also rose, gaining, 1.06% to 4,831.75.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Friday. The Dow traded up 0.41% to 37,621.27 while the NASDAQ rose 0.66% to 15,154.43. The S&P 500 also rose, gaining, 0.46% to 4,803.12.
Newly granted patent protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of ichthyosis vulgaris
Ichthyosis vulgaris is a high unmet need with no FDA-approved.
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,850,267 covering future.